Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020

Abstract
Biosimilars are biopharmaceutical drugs that are highly similar to already approved biological product (also known as biological reference product). Biosimilars are unique and can never be identical to the reference product as these are grown in living cells. Biosimilars are not generics but have close proximity to generic version of various biologics. The emergence of biologics had already revolutionized treatment options for large variety of diseases. There is increased market opportunity for biosimilars with majority of biologics losing exclusivity in upcoming years. Biosimilars has substantial potential to increase access to biological therapies while enhancing cost-effectiveness of healthcare systems globally.

Growing demand for biosimilars and biologics worldwide is demonstrated by magnitude of biological patent expiries, cost savings associated with use of biosimilars and increased use of biosimilars for treatment of chronic diseases. Major market restraints biosimilars market are high cost of development of biosimilars, regulatory uncertainty, lower adoption rate of biosimilars and manufacturer skill gap. Some of the leading industry trends and developments include new biosimilar products dominated by Large Globals, increased focus on pharmerging markets and issuance of much-awaited biosimilar interchangeability guidance by FDA.

The report provides information on the current scenario, detailed market outlook of the global biosimilar market. Detailed analysis of Biosimilar market segmentation by application area – Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) has been covered in the report. Future forecasts of major segments as well as biosimilar markets in developed and emerging nations till 2020 is provided in the report. Furthermore, key industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the market include Biocad, TEVA, Celltrion, Sandoz, Dong-A Pharmaceutical Co., Ltd., Hospira, Intas, Stada Arzneimittel, among others. Sandoz, Hospira, TEVA, Celltrion, Biocad and Dong-A Pharmaceutical Co., Ltd. are profiled herein based on attributes such as business overview, product pipeline, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global biosimilars market in both developed and emerging economies.

Content
1. Executive Summary
2. Research Methodology
3. Introduction
4. Global Biologics Market
4.1 OVERVIEW
4.1.1 Classification of Biologics
4.2 GLOBAL BIOLOGICS MARKET ANALYSIS
1.1.1 Market Sizing (Actual & Forecasted)
5. Global Biosimilars Market
5.1 OVERVIEW
5.2 MARKET ANALYSIS
5.2.1 Market Sizing (Actual & Forecasted)
2.1.1 Market Share by Region (Actual & Forecasted)
3.1.1 Market Share by Application (Actual & Forecasted)
4.1.1 Market by Product Pipeline
6. Global Biosimilars Market Segmentation
6.1 ERYTHROPOIETIN (EPO)
6.1.1 Overview
6.1.2 Market Analysis
6.2 INSULIN
6.2.1 Overview
6.2.2 Market Analysis
6.3 HUMAN GROWTH HORMONE (HGH)
6.3.1 Overview
6.3.2 Market Analysis
6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF)
6.4.1 Overview
6.4.2 6.4.2 Market Analysis
6.4.2 6.4.2 Market Analysis
6.5 MONOCLONAL ANTIBODY (MAB)
6.5.1 Overview
6.5.2 Market Analysis
6.6 INTERFERON (IFN)
6.6.1 6.6.1 Overview
6.6.2 Market Analysis
7. Global Biosimilars Market Analysis – Developed & Emerging Nations
7.1 DEVELOPED MARKET
7.1.1Europe
7.1.2 The US
7.2 EMERGING MARKET
7.2.1 China
7.2.2India
8. Global Biosimilars – Pricing Analysis
9. Global Biosimilar Industry – SWOT Analysis
10. Global Biosimilars Market Attractiveness Index
11. Global Biosimilars Market Dynamics
11.1 INDUSTRY TRENDS & DEVELOPMENTS
11.1.1 New Biosimilars Dominated by Large Globals
11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA
11.1.3 11.1.3 Focus on Pharmerging Markets
11.2 GROWTH DRIVERS
11.2.1 11.2.1 Biological Patent Expiries
11.2.2 11.2.2 Cost saving
11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases
11.3 CHALLENGES
11.3.1 11.3.1 High Cost of Development
11.3.2 11.3.2 Regulatory Uncertainty
11.3.3 11.3.3 Lower Adoption Rate of Biosimilars
11.3.4 11.3.4 Manufacturer Skills Gap
12. Competitive Landscape
12.1 MARKET SHARE BY COMPETITORS
12.2 MARKET SHARE BY DRUGS
13. Company Profiles
13.1 SANDOZ
13.2 HOSPIRA
13.3 TEVA
13.4 CELLTRION
13.5 BIOCAD
13.6 DONG-A PHARMACEUTICAL CO., LTD
13.7 STADA